Cite
Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: A post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS)
MLA
Li, Jian-Jun, et al. “Impact of Long-Term Xuezhikang Therapy on Cardiovascular Events in High-Risk Patients with Nonspecific, Preexisting Abnormal Liver Tests: A Post-Hoc Analysis from Chinese Coronary Secondary Prevention Study (CCSPS).” International Journal of Cardiology, vol. 154, no. 3, Feb. 2012, pp. 362–65. EBSCOhost, https://doi.org/10.1016/j.ijcard.2011.11.005.
APA
Li, J.-J., Lu, Z.-L., Kou, W.-R., Bolli, R., Chen, Z., Wu, Y.-F., Yu, X.-H., & Zhao, Y.-C. (2012). Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: A post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS). International Journal of Cardiology, 154(3), 362–365. https://doi.org/10.1016/j.ijcard.2011.11.005
Chicago
Li, Jian-Jun, Zong-Liang Lu, Wen-Rong Kou, Roberto Bolli, Zuo Chen, Yang-Feng Wu, Xue-Hai Yu, and Yu-Cheng Zhao. 2012. “Impact of Long-Term Xuezhikang Therapy on Cardiovascular Events in High-Risk Patients with Nonspecific, Preexisting Abnormal Liver Tests: A Post-Hoc Analysis from Chinese Coronary Secondary Prevention Study (CCSPS).” International Journal of Cardiology 154 (3): 362–65. doi:10.1016/j.ijcard.2011.11.005.